

III. REMARKS

Summary of the Amendments

The specification was amended to correct the priority claim.

The structure found on page 5, after line 17, was moved to page 5, after line 18, to be consistent with the language recited therein.

Claims 1-49 have been canceled.

New Claims 50-55 are directed to compounds identified as (1C), (2C), (3C), (4C), and (5C), and are supported, for example, on page 39, lines 1-13; page 42, line 5 through page 43, line 12; page 45, lines 4-6; page 89, line 1 through page 90, line 10; page 90, lines 16-30; page 91, lines 10-15; Figure 5; and original Claim 4 of the original specification as filed.

New Claim 56 is directed to a pharmaceutical composition, and is supported by original Claims 13-17 of the original specification as filed.

New Claims 57-59 are directed to a method of treatment. Support for these amendments may be found on page 3, lines 13-17; page 84, lines 9-15; and Claims 18-22 of the original specification as filed.

No new matter has been added. Entry of these amendments is requested.

Priority

Upon review, Applicants do not claim domestic priority under 35 U.S.C. § 119(e) for Claims 50-59, the claims now pending in the application. Accordingly, the specification has been amended to delete Applicants' priority claim under 35 U.S.C. 119(e).

Additionally, the specification has been amended to claim priority under 35 U.S.C. § 120 as a continuation application to parent application, USSN 09/674,451, now allowed.

Change in Inventorship

Applicants have reviewed inventorship of pending Claims 50-59 and have determined that inventor John Griffin, who was correctly named as an inventor in parent application, USSN 09/674,451, as filed, is not an inventor of the claimed subject matter.

Accordingly, Applicants submit herewith a petition pursuant to 37 CFR. §1.48(b) to delete a correctly named person who is not an inventor of the invention now being claimed with authorization to charge the requisite fee under CFR §1.17(i).

Conclusion

Applicants have corrected errors in the specification, canceled Claims 1-49, and added new Claims 50-59. Early entry of these amendments is requested. Applicants respectfully request examination on the merits for the above-identified application.

Respectfully submitted,

Date: Jan. 30, 2004

By: Joyce Cohen
Joyce Cohen, Reg. No. 44,622

THERAVANCE, INC.
Attn: Legal Dept.
901 Gateway Boulevard
South San Francisco, CA 94080
Tel: (650) 808-6000
Fax: (650) 808-6078